Silver and nanoparticles of silver in wound dressings: a review of efficacy and safety

Journal of wound care - Tập 20 Số 11 - Trang 543-549 - 2011
Legh Wilkinson1, Richard White2, J.K. Chipman1
11 School of biosciences, The University of birmingham, UK
22 Institute of Health and Society, University of Worcester, UK

Tóm tắt

Wound infections present a significant clinical challenge, impacting on patient morbidity and mortality, with significant economic implications. Silver-impregnated wound dressings have the potential to reduce both wound bioburden and healing time. The silver ion Ag+ is the active antimicrobial entity; it can interfere with thiol (−SH) groups and provoke the generation of reactive oxygen species (ROS), a major contributor to its antibacterial efficacy. Recently, silver nanoparticles have gained considerable interest in wound bioburden reduction and in anti-inflammation, as they can release Ag+ ions at a greater rate than bulk silver, by virtue of their large surface area. If released from dressings, they also have the potential to cross biological compartments. This review aims to consolidate recent findings as to the efficacy and safety of different formulations of silver used as an antiseptic agent in dressings, summarising the features of silver nanomaterials, with particular attention to the dose-dependencies for biological effects, highlighting the need for information on their uptake and potential biological effects.

Từ khóa


Tài liệu tham khảo

Cooper R., 2005, Wounds-UK., 1, 51

10.1155/2010/910686

10.1016/j.tibtech.2010.07.006

AshaRani P.V., 2009, ACS Nano., 24, 2

10.1080/17435390902725914

10.1007/s10295-006-0139-7

10.1016/j.jhin.2004.11.014

10.1099/jmm.0.46124-0

Walker M., 2006, Ostomy Wound Manage., 52, 42

Nadworny P.L., 2008, J Wound Technology., 2, 6

10.1016/j.ymthe.2005.07.684

10.1016/S0006-291X(74)80175-0

10.1046/j.1524-475X.2002.10308.x

10.1111/j.1365-2230.2004.01515.x

10.1111/j.1365-2133.2005.06575.x

10.1186/1476-9255-7-13

10.1186/1471-2121-10-65

10.1016/j.addr.2009.03.005

10.1021/pr0504079

10.1289/ehp.0901398

Wan A.T., 1991, Clin Chem., 37, 1683, 10.1093/clinchem/37.10.1683

10.3109/10408449509049339

10.1093/toxsci/kfm169

10.3109/10408440903453074

10.12968/jowc.2005.14.4.26762

10.1093/annhyg/mei019

10.1016/j.envint.2010.10.012

10.1002/cmdc.200900502

10.1016/j.cca.2010.08.016

10.1093/toxsci/kfq372

10.1016/j.bbagen.2010.04.007

World Health Organisation (WHO), 1996, Health criteria and other supporting information, 2, 2

10.1097/01.ta.0000208126.22089.b6

10.1080/10408440601177665

10.1166/jnn.2010.2625

Choksi A.N., 2010, J Drugs Dermatol., 9, 475

10.12968/jowc.2003.12.9.26534

10.1097/00006534-196606000-00012

10.1016/j.toxlet.2007.10.004

10.1016/j.toxlet.2010.12.001

10.1016/j.tiv.2009.06.001

10.1021/nn800596w

10.1016/j.freeradbiomed.2008.01.028

10.1016/j.taap.2009.02.020

10.1016/j.taap.2009.10.016

10.1016/j.bbabio.2008.09.006

10.1016/S1569-2582(97)80115-8

10.1016/j.taap.2008.09.015

10.1007/s00204-010-0545-5

10.1159/000237765

10.1007/BF00141061

10.1007/s10529-008-9786-2

10.1016/j.toxlet.2008.04.009

10.1016/j.scitotenv.2007.10.010

10.1016/j.jclepro.2007.04.007

10.1016/S0048-9697(03)00139-6

10.1016/S1001-0742(10)60412-3

10.1016/j.aquatox.2010.09.010

Yeo M.K., 2009, Mol Cell Toxicol., 5, 23

10.1016/j.trac.2011.01.008

10.1016/j.taap.2008.09.015

10.1016/0305-4179(92)90067-5

10.12968/jowc.2011.20.4.192